Q4 Earnings Estimate for VKTX Issued By B. Riley

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities research analysts at B. Riley issued their Q4 2024 earnings estimates for shares of Viking Therapeutics in a report issued on Thursday, November 21st. B. Riley analyst M. Mamtani anticipates that the biotechnology company will post earnings per share of ($0.24) for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.98) per share. B. Riley also issued estimates for Viking Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($1.83) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same period in the previous year, the business earned ($0.23) EPS.

Other analysts have also recently issued research reports about the stock. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research report on Tuesday, October 15th. JPMorgan Chase & Co. initiated coverage on shares of Viking Therapeutics in a research report on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 price target for the company. HC Wainwright upped their price objective on Viking Therapeutics from $90.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Oppenheimer reiterated an “outperform” rating and issued a $138.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, September 25th. Finally, Morgan Stanley reissued an “overweight” rating and set a $105.00 target price on shares of Viking Therapeutics in a research note on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $109.73.

Viking Therapeutics Price Performance

Shares of Viking Therapeutics stock opened at $51.99 on Monday. The stock has a market capitalization of $5.79 billion, a price-to-earnings ratio of -55.90 and a beta of 1.00. The business has a 50-day moving average of $63.43 and a 200 day moving average of $60.05. Viking Therapeutics has a 12 month low of $11.55 and a 12 month high of $99.41.

Insider Transactions at Viking Therapeutics

In other news, Director J Matthew Singleton sold 10,300 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $69.50, for a total transaction of $715,850.00. Following the completion of the sale, the director now owns 9,500 shares in the company, valued at approximately $660,250. The trade was a 52.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian Lian sold 216,130 shares of the company’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $70.83, for a total transaction of $15,308,487.90. Following the completion of the transaction, the chief executive officer now owns 2,304,927 shares of the company’s stock, valued at approximately $163,257,979.41. The trade was a 8.57 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 371,117 shares of company stock valued at $27,140,009. 4.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Viking Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Blue Trust Inc. purchased a new position in Viking Therapeutics during the 3rd quarter worth approximately $26,000. GAMMA Investing LLC grew its position in shares of Viking Therapeutics by 124.6% during the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 243 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Viking Therapeutics in the 2nd quarter valued at $27,000. Stone House Investment Management LLC increased its holdings in shares of Viking Therapeutics by 66.7% in the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 200 shares during the period. Finally, Gilliland Jeter Wealth Management LLC purchased a new stake in Viking Therapeutics in the 3rd quarter valued at $32,000. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.